J&J’s first pso­ri­a­sis study ex­clu­sive to pa­tients of col­or opens door to new mar­ket­ing com­mu­ni­ca­tions

John­son & John­son’s first-ever clin­i­cal study in pso­ri­a­sis with pa­tients of col­or found its treat­ment Trem­fya works sim­i­lar­ly across di­verse pop­u­la­tions, but that’s not the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER